Cited by 244Pharmaceutical studies and practicesStatistical Methods in Clinical TrialsPharmacogenetics and Drug Metabolism

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance

Open access

Jamei, Masoud·2016·Current Pharmacology Reports

DOI 10.1007/s40495-016-0059-9PMC PMC4856711

Open this paper in CoChat — free account Open PDF

Abstract

There is a renewed surge of interest in applications of physiologically-based pharmacokinetic (PBPK) models by the pharmaceutical industry and regulatory agencies. Developing PBPK models within a systems pharmacology context allows separation of the parameters pertaining to the animal or human body (the system) from that of the drug and the study design which is essential to develop generic drug-independent models used to extrapolate PK/PD properties in various healthy and patient populations. This has expanded the classical paradigm to a 'predict-learn-confirm-apply' concept. Recently, a number of drug labels are informed by simulation results generated using PBPK models. These cases show that either the simulations are used in lieu of conducting clinical studies or have informed the drug label that otherwise would have been silent in some specific situations. It will not be surprising to see applications of these models in implementing precision dosing at the point of care in the near future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s40495-016-0059-9

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 A schematic of systems pharmacology paradigm where the systems, drug and trial design data are mechanistically combined and integrated within PBPK models to simulate and predict the drug PK/PD in virtual populations. The Systems and Data are part of the trial setting thence included in the Trial Design boxCC BY · PubMed Central

Fig. 2 The distribution of area of applications of 136 regulatory submissions to FDA (until Oct 2014) where PBPK modelling has been applied, updated by Grillo [10] after [14]CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions
Rodgers, T., & Rowland, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20502 · Cited by 949
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification
Sager, J. E., Yu, J., Ragueneau, I., & Isoherranen, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065920 · Cited by 541
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Rostami‐Hodjegan, A., & Tucker, G. T. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2173 · Cited by 533
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
Zhao, P., Zhang, L., Grillo, J. A., Liu, Q., Bullock, J. M., Moon, Y. J., Song, P., Brar, S. S., Madabushi, R., Wu, T. C., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.298 · Cited by 524
Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective
Jones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M., & Hall, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.37 · Cited by 488
A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates
Jamei, M., Dickinson, G. L., & Rostami‐Hodjegan, A. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.53 · Cited by 377
Self-citation
Physiologically Based Pharmacokinetics Joined with In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology
Rostami-Hodjegan, A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.65 · Cited by 331
Prediction of Pharmacokinetics Prior to In Vivo Studies. II. Generic Physiologically Based Pharmacokinetic Models of Drug Disposition
Poulin, P., & Theil, F. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10128 · Cited by 303
Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK
Wagner, C., Zhao, P., Pan, Y., Hsu, V, Grillo, J., Huang, S., & Sinha, V (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.33 · Cited by 276

Show all 41 references

Sorted by citations

Items 201–244 of 244

Exploring the Impact of Developmental Clearance Saturation on Propylene Glycol Exposure in Adults and Term Neonates Using Physiologically Based Pharmacokinetic Modeling
Olafuyi, O., Michelet, R., Garle, M. J., & Allegaert, K. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6150 · Cited by 2
Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic Modeling
Jaiswal, S., Patel, N. K., Jones, H. M., McFeely, S. J., Faison, S. L., Tippin, T., & Naderer, O. J. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70093 · Cited by 2
Demonstration of in vitro-in vivo relationship (IVIVR) and virtual bioequivalence (VBE) between progesterone intravaginal rings using physiologically based pharmacokinetic (PBPK) modelling
Thakur, K., Sternebring, O., Zhang, Y.-E., Wyckoff, K., MacDonald, I. I., Pinton, P., Paterson, D., Telaprolu, K. C., & Polak, S. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.104046 · Cited by 2
Virtual Bioequivalence Assessment of Long-acting Injectable Suspensions Using PBPK Modeling: Part 1. Impact of particle Size on Formulation Variability
Morris, N. M., Djehizian, A., Mittapelly, N., Telaprolu, K. C., Holland, B. W., McNally, K., Polak, S., Jamei, M., Alam, K. D., Tsakalozou, E., et al. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01213-2 · Cited by 2
Self-citation
Impact of Preclinical Verification in Physiologically Based Pharmacokinetic Modelling for First-in-Human Predictions: Application of a Published Model Building Strategy for Five Compounds
Jackson, C., Graves, R. H., Tran, T. T., & Miller, N. A. (2026) · Clinical Pharmacokinetics · doi:10.1007/s40262-026-01655-z · Cited by 2
Physiologically based pharmacokinetic modeling to characterize enterohepatic recirculation and predict food effect on the pharmacokinetics of hyzetimibe
Chen, W., Ruan, Z., Lou, H., Yang, D., Chen, J., Shao, R., & Jiang, B. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106576 · Cited by 2
Complementarity of two proteomic data analysis tools in the identification of drug-metabolising enzymes and transporters in human liver
Vasilogianni, A., Alrubia, S., El‐Khateeb, E., Al‐Majdoub, Z. M., Couto, N. A. S., Achour, B., Rostami‐Hodjegan, A., & Barber, J. (2023) · Molecular Omics · doi:10.1039/d3mo00144j · Cited by 2
Physiologically Based Pharmacokinetic Modeling of Vitamin B-12 Incorporating Mechanistic Absorption: An Example Application for Intake Estimation During Pregnancy
Zhang, M., Almond, L. M., & Jones, H. M. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.07.019 · Cited by 2
Pharmakokinetische und pharmakodynamische Modellierung bei Kinderarzneimitteln: Schwerpunkt Physiologie-basiertes pharmakokinetisches Simulieren
Läer, S. (2019) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2019.03.003 · Cited by 2
A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections
Mtshali, S., & Jacobs, B. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00274-22 · Cited by 2
DDI and Drug Development
Erceg, D., & Amidzic, A. A. (2024) · Clinical gastroenterology · doi:10.1007/978-3-031-69800-2_4 · Cited by 2
Utilizing physiologically based pharmacokinetic modeling to predict theoretically conceivable extreme elevation of serum flecainide concentration in an anuric hemodialysis patient with cirrhosis
Doki, K., Kuga, K., Aonuma, K., Ieda, M., & Homma, M. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02861-9 · Cited by 2
Application of the Simcyp Population‐based PBPK Simulator to the Modelling of MR Formulations
Patel, N. K., Pathak, S. M., & Turner, D. B. (2022) · doi:10.1002/9781119772729.ch20 · Cited by 2
Applications of PBPK Modeling and Simulations in The Clinical Pharmacology Field: Lessons from Several Case Studies
Emoto, C., Doki, K., Matsumoto, Y., Kijima, S., Nakamura, M., & Fukuda, T. (2020) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.51.331 · Cited by 1
Pharmacokinetics and Toxicokinetics in Drug Development
Licollari, A., & Bolger, G. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85704-8.00002-5 · Cited by 1
The Role of Cross-Institutional and Interdisciplinary Collaboration in Defining and Executing a Quantitative Systems Pharmacology Strategy
Vicini, P., & van der Graaf, P. H. (2024) · Handbook of experimental pharmacology · doi:10.1007/164_2024_736 · Cited by 2
Physiologically based pharmacokinetic and toxicokinetic modeling: A multidisciplinary approach to drug development and ecotoxicology
Todorović, N., Ćoškov, A., Andric, N. L., Stanić, B., Milijašević, B., Milošević, N., Јаnkovic, S., & Lalic-Popovic, M. N. (2025) · Hospital Pharmacology - International Multidisciplinary Journal · doi:10.5937/hpimj2502692t · Cited by 1
Indirect Modeling of Post-Prandial Intestinal Lymphatic Uptake of Halofantrine Using PBPK Approaches: Limitations and Implications
Yousef, M., Mosa, F. E. S., Barakat, K., Davies, N. M., & Löbenberg, R. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091228 · Cited by 1
Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study
Burnett, J., Sychterz, C. J., Katz, J. B., Shakeel, F., Silva, J., Chen, W., Shahane, A., Wang, X., Lamba, M., & Gaudy, A. M. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70082 · Cited by 1
Integrated Physiologically-based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 2: MIDD and MIPD Applications
Garcia, L. P., Nordell, P., Ahlström, C., Lennernäs, H., & Sjögren, E. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01137-3 · Cited by 1
Mechanistic Modelling of Lidocaine and Prilocaine Absorption from EMLA Cream upon Topical Application using Physiologically Based Pharmacokinetic Modelling
Telaprolu, K. C., Tsakalozou, E., Ghosh, P., Alam, K., Grice, J. E., Roberts, M. S., Jamei, M., Polak, S., & Clarke, J. F. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03232-2 · Cited by 1
Self-citation
Pharmacometrics-driven dose individualization of modified-release formulations: integration of PopPK, PBPK, and PK/PD modeling
Rasool, B. K. A., Ali, I. S. M., & Shahiwala, A. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101701 · Cited by 1
A Reliable and Effective UPLC-MS/MS Method for the Determination of Oprozomib in Rat Plasma
Li, X., Liu, Y., Zhang, E., Xu, R.-A., Yang, T., & Luo, S. (2023) · Journal of Analytical Methods in Chemistry · doi:10.1155/2023/3678599 · Cited by 1
Linking in vitro–in vivo extrapolations with physiologically based modeling to inform drug and formulation development
Cristofoletti, R., & Rostami‐Hodjegan, A. (2023) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2375 · Cited by 1
Modular dynamics paradigm in biosystems multilevel modeling: Software design and PBPK/PD validation
Prado-Velasco, M. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109856 · Cited by 1
Formulation development and characterization
Dezfooli, S. M., Dkhar, L., Long, A., Gholizadeh, H., Mohammadi, S., Greene, C. A., & Seyfoddin, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102548-2.00003-2 · Cited by 1
Nonclinical drug development
Takimoto, C. H. M., Wick, M. J., Agoram, B. M., & Jin, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00031-8 · Cited by 1
Physiologically based pharmacokinetic models to support modernized chemical safety assessment
Yoon, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818596-4.00012-6
A latent variable approach to account for correlated inputs in global sensitivity analysis with cases from pharmacological systems modellingPreprint
Melillo, N., & Darwich, A. S. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2012.02500
Enabling personalized medicine through pharmacokinetic modeling
Scherholz, M. L. (2019) · doi:10.7282/t3-2ry2-4f60
Physiologically Based Pharmacokinetic (PBPK) Modeling: Applications in Drug Development
Ibarra, M., Schiavo, A., & Lesko, L. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-51519-5_169-1
A human population-based organotypic in vitro model for cardiotoxicity screening_suppl
Grimm, F. A. (2018) · ALTEX · doi:10.14573/altex.1805301s
Physiologically Based Pharmacokinetic (PBPK) Modeling: Applications in Drug Development
Ibarra, M., Schiavo, A., & Lesko, L. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-84860-6_169
Physiologically based population pharmacokinetic/pharmacodynamic modeling and simulation approaches to support waivers of in vivo clinical pharmacology studies
Loisios-Konstantinidis, I. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.70789
Application of Virtual Drug Study to New Drug Research and Development: Challenges and Opportunity
Li, X., Liu, S., Liu, D., Yu, M., Wu, X., & Wang, H. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01416-w
Using the Simcyp R Package for PBPK Simulation Workflows With the Simcyp Simulator
Onasanwo, A., Mittapelly, N., Shireman, L. M., Vinden, B., McNally, K., Craig, J., & Bois, F. Y. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70022
Simultaneous Estimation of fm and FG Values Directly from Clinical Drug-Drug Interaction Study Data
Cleary, Y., Milani, N., Ogungbenro, K., Aarons, L. J., Galetin, A., & Gertz, M. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01064-3
Physiologically Based Pharmacokinetic Simulation of Tofacitinib in Humans Using Extrapolation from Single-Species Renal Failure Model
Bae, S. H., Park, S. Y., Choi, H. G., & Kim, S. H. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070914
Utility of Modeling and Simulations in Drug Development: Contrasting Japan, US and UK Descriptions of PBPK Modeling from Package Inserts
Kudo, S., Wakuda, H., Oikawa, I., Sekiguchi, A., Nakamura, Y., Hojo, T., Imai, H., Kai, M., & Uemura, N. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01211-4
PBPK modeling of doxorubicin-loaded polymeric nanoparticles : potential for clinical translation
Chao, F.-C. (2023) · theses.fr (ABES) · doi:10.70675/7bcf6d06za15fz452fz9b70z8697a902c896
Development and application of a CNS PBPK model that integrates CSF dynamics to optimize dosing regimens of antibacterial agents in pediatric patients with meningitis
Shen, C., Zheng, Y., Liu, B., Wu, Y., Chenshuang, Z., Yang, L., Wang, X., Wang, Y., Xie, H., Jiang, X., et al. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107857
From meal to medicine: exploring the roots and consequences of drug-food effects
Löbenberg, R., Kabalan, J., Macfarlane, B., Djebbouri, S., Daunoras, S., Mougarbel, T., Qeshanna, M., Pham, P., Davies, N. M., Bou‐Chacra, N. A., et al. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00825-2
PBPKO: an ontology for standardizing and harmonizing physiologically based pharmacokinetic (PBPK) models
Kumar, S., Sharma, S., Panov, P., Kruisselbrink, J. W., Moreno, A., Deepika, D., & Kumar, V. (2026) · Computational Toxicology · doi:10.1016/j.comtox.2026.100445
Transitioning from Transcriptomics to Proteomics: Enhancing Mechanistic Accuracy in PBPK Modeling via Absolute Protein Abundances
Chen, N., Pugliano, A., Winter, M., Wu, K., & Annaert, P. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70316

Authors: Jamei, M.
Affiliations: Simcyp (United Kingdom) (GB)
Corresponding author: Jamei, Masoud
ORCID: Jamei, Masoud
Venue: Current Pharmacology Reports
Publisher: Springer Science and Business Media LLC
Published: 2016-04-14
Volume: 2
Issue: 3
Pages: 161-169
ISSN: 2198-641X (ISSN-L)
DOI: 10.1007/s40495-016-0059-9
PMC: PMC4856711
OpenAlex: W2341647963
Cited by: 244
References: 41
Citations by year: 2026: 10 · 2025: 21 · 2024: 17 · 2023: 29 · 2022: 20 · 2021: 25 · 2020: 31 · 2019: 24 · 2018: 24 · 2017: 37 · 2016: 6
FWCI: 4.70
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (unspecified)
Locations: Current Pharmacology Reports (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: Simcyp Limited (A Certara Company)
Topics: Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords: physiologically based pharmacokinetic modeling, regulatory acceptance, systems pharmacology, precision dosing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks